Rolapitant Phase III results for CINV (Nausea)- Tesaro
Tesaro Inc. has announced top-line results for two Phase III trials of rolapitant, an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV). The primary endpoint was successfully achieved in each trial although statistical significance was not met for the secondary endpoints.
Tesaro continues to enroll patients receiving highly emetogenic chemotherapy (HEC) in a third and final Phase III trial of rolapitant, and preparations in support of a mid-2014 NDA submission for oral rolapitant are ongoing.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.